Company intelligence / Profile preview
Sumitomo Pharma
Osaka, Osaka, Japanus.sumitomo-pharma.com ↗
- Ownership
- Public · 4506
- Employees
- ~4767
- Development stage
- Commercial
01
Overview
Sumitomo Pharma has several commercialized drugs in psychiatry/neuroscience and urology/women's health. It continues to advance a robust pipeline with late-stage assets in cell therapy for Parkinson’s disease and retinal disorders. The company faces financial headwinds post-patent expiry of key products but remains active in global R&D with a strategic pivot toward innovation-driven growth.
- Therapeutic areas
- OncologyRare DiseasesPsychiatryNephrologyWomen's Health
- Modalities
- Small molecule drugsSynthetic peptidesInduced pluripotent stem cells (iPSC)/cell therapyTherapeutic vaccines
- Industry
- Biotech
02
Drug pipeline
59 assets58 more assets in the full pipeline.
Request access →03
Partnerships
Strategic alliance with Roivant Sciences led to creation of “Sumitovant Biopharma” holding Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics among others.Other partnerships exist with academic institutions and biotechs.
Beyond the preview
Go deeper on Sumitomo Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sumitomo Pharma.